US Grant Recipients
Since its creation in 1996, the Jérôme Lejeune Foundation has provided research grants in order to find therapeutic treatments for Trisomy 21 (Down syndrome) and other Genetic Intelligence Disabilities, providing some $21 million worldwide including over $3 million in the United States.
The Jérôme Lejeune Foundation supports therapeutic research programs in the United States and all over the world. Grant applications submitted by US researchers are reviewed and selected by the US Scientific Committee of the Foundation’s International Scientific Advisory Board. This Board meets twice a year to award grants.
Grant Recipients list:
Per last name: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Per year:
- 2012-2013
- 2011-2012
- 2010-2011
- 2009-2010
- 2008-2009
- 2007-2008
- 2006-2007
- 2005-2006
- 2004-2005
- 2003-2004
- 2002-2003
- 2001-2002
- 2000-2001
- 1999-2000
- 1998-1999
B:
Dr. Emily BROOKES- Boston, Massachusetts
2012-2013: Elucidating the role of histone demethylase SMCX in intellectual disability using human induced pluripotent stem cells
Dr. Anita BHATTACHARYYA – Madison, Wisconsin; [Profile]
2007-2008: Generation of human trisomy 21 pluripotent cells
Mr. Tyler BEST – Bethesda, Maryland
2003-2004: PIP2 modulation of channel current GIRK in Trisomy 21
C:
Dr. Aurore CURIE Charlestown, Massachusettes
2012-2013: Study of neuronal networks and cognitive mechanisms involved in X linked intellectual disability
Dr. Alberto COSTA – Denver, Colorado. [Article], [Interview 1], [Interview 2]
2006-2007: Preclinical Development of Targeted Pharmacotherapy at Associated Hypomyelination to Down Syndrome
Dr. Dana CRAWFORD – Albany, New York. [Profile]
2009-2010: The role and targeting of RCAN1 in Down Syndrome
2004-2005: Involvement of the over-expression of the gene in the neuron adapt78 in Trisomy 21
D:
Dr. Gilbert DI PAOLO – New York, New York. [Profile], [Interview]
2009-2010: Lipid Imbalance and endosomal dysfunction in Down syndrome – A lipidomic approach
2006-2007: Role of the over-expression of Synj1 in cognitive deficits in mouse models for Trisomy 21
2003-2004: Study of the metabolism of PIP2 in a mouse model of Trisomy 21
E:
Dr. Sarah ELSEA – Richmond, Virginia. [Profile]
2010-2011: Development and characterization of a neuronal model system for analysis of compounds to modulate RAI1 expression in Smith-Magenis syndrome
2008-2009: Defining the critical genes for disorders of behavior and developmental delay on chromosomes 2q37.3 and 2q23.1
2006-2007: Identification of loci responsible for disorders in mental retardation near the Smith-Magenis syndrome
Dr. Jamie EDGIN – Tucson, Arizona
2009-2010: Aging and Dementia in Down Syndrome: Neuropsychological Profile and Intervention
Dr. Terry ELTON – Colombus, Ohio. [Profile]
2008-2009: Down Syndrome and MicroRNAs
F:
Dr. Gene FISCH – New York, New York
2007-2008: Longitudinal studies of children with subtelomeric deletions causing mental handicap
2005-2006: Longitudinal studies of subtelomeric deletions cause of mental disability
G:
Mr. Zygmunt GALDZICKI – Bethesda, Maryland. [Profile]
2004-2005: Signaling pathways in platelets of patients and mouse models of Trisomy 21
2001-2002: The impact of kainate receptor over-expression on brain and spinal cord synaptic plasticity in mouse TS65DN – Animal Model of Down Syndrome
Dr. Katheleen GARDINER – Denver, Colorado. [Interview]
2012-2013: Workshop on Cognition in Down syndrome: molecular, cellular and behavioral features and the promise of therapeutics
2011-2012: Comparative analysis of drug responses in mouse models of Down syndrome
2009-2010: Perturbation of signaling pathways in the Tc1 mouse model of Down Syndrome
2008-2009: Stabilizing post translational modification (PTM) in tissue samples
2006-2007:
- Conference on the Biology of genes on chromosome 21: correlation to gene/phenotype in Trisomy 21
- Perturbation of signaling pathways: application to cognitive defects and Trisomy 21
- Data mining for gene-phenotype and drug response correlations in Down syndrome
2004-2005: A database of chromosome 21/Trisomy 21
2003-2004: Abnormalities of MAP kinase and calcineurin in mouse models of Trisomy 21
2002-2003: Expert Meeting on the gene-phenotype correlations in Trisomy 21
2000-2001: Candidate genes for the phenotype of Trisomy 21: analysis of their expression in the normal and trisomic cell lines 21 and in murine models
1998-1999: Analysis of the expression of known genes and new genes in cell lines trisomic and normal, and animal models
H:
Ms. Janet L. HAUCK – Ann Arbor, Michigan. [Profile]
2009-2010: Promoting physical activity in young children with Down syndrome
Dr. H.Graig HELLER – Stanford, California. [Profile]
2007-2008: GABA based pharmacotherapy essays for improving cognition through the consolidation of sleep and wake in Ts65Dn mice
Dr. Yu-Wen HWANG – Staten Island, New York
2006-2007: Regulation Of The assembly of endocytic complex by Dyrk1A
K:
Pr. Jan Peter KRAUS – Aurora, Colorado. [Profile], [Website]
2009-2010: Targeting misfolding in homocystinuria
2006-2007: CBS: A Key Enzyme Involved in homocysteine metabolism and hydrogen sulfide
2004-2005: Mouse models of deficiency Homocystinuria Cystathionine beta synthase (CBS)
L:
Dr. Heather LEHMAN – Buffalo, New York. [Profile]
2008-2009: Humoral Immunodeficiency in Pediatric Down Syndrome Patients
M:
Dr. Kenneth MACLEAN – Aurora, Colorado
2008-2009: Novel Pathogenic Mechanisms and Treatment for Cognitive Impairment in CBS Deficient Homocystinuria
Dr. Jean-Bernard MANENT – Storrs, Connecticut
2006-2007: Investigating the reversibility of neuronal migration disorders in animal model year of double cortex syndrome
Pr. Emmanuel MIGNOT – Palo Alto, California. [Profile]
2003-2004: The cycle of sleep in a model of Trisomy 21: metabolic implications
Dr. Michael MILES – Cincinnati, Ohio. [Profile]
2005-2006: Evaluation of effectiveness of coenzyme Q10 (uniquinone) in children with Trisomy 21
Dr. Kyung-Tai MIN – Bethesda, Maryland
2011-2012: Investigating the biological pathways shared between Down syndrome and Fragile X syndrome
2005-2006: Using Drosophila to study the etiology of Alzheimer’s disease in Trisomy 21
N:
Pr. Lynn NADEL –Tucson, Arizona. [Profile]
2011-2012: High density EEG biomakers of memory dysfunction in Down syndrome
O:
Dr. John O’BRYAN – Chicago, Illinois. [Profile]
2008-2009: Defining intersectin (ITSN) function in Down Syndrome
Mr. Mustafa Nazir OKUR – Chicago, Illinois
2011-2012: Intersectin regulation of EGFR ubiquitylation and degradation
P:
Dr. David PATTERSON – Denver, Colorado. [Profile]
2005-2006: Mouse models over-expressing or knockout the gene of the reduced folate carrier (RFC): study of the role of RFC in Trisomy 21
2003-2004: Production and use of transgenic mice CBS to understand the role of this enzyme in Trisomy 21
2002-2003: Role of mitochondrial proteins and metabolic response in the mouse model Ts65Dn Trisomy 21
2001-2002: Effect of a diet rich in antioxidants to prevent the loss of cholinergic neurons and cognitive decline in mice
1999-2000: Study of the variation in purine diet and folate on a mouse model of Trisomy 21
R:
Dr. Shannon RINGENBACH – Tempe, Arizona. [Profile]
2008-2009: Examination of intra and interhemispheric processing following different instructiong during long term motor learning in persons with Down syndrome
2006-2007: Music and Movement in Persons with Down Syndrome
Pr. Randal ROPER – Indianapolis, Indiana. [Profile]
2010-2011: Mechanisms of craniofacial and appendicular bone development disrupted by trisomy in Down syndrome
Dr. Sandra RYEOM – Boston, Massachussetts
2008-2009: Down Syndrome: Protection against cancer and the role of the Down syndrome candidate region-1 gene
S:
Pr. Mark SCHAPIRO – Cincinnati, Ohio. [Profile]
2002-2003: Study of language processing by functional magnetic resonance imaging in individuals with Trisomy 21
Ms. Ann C.M. SMITH – Bethesda, Maryland
2007-2008: Comparative Behavioral Phenomics: Investigation of structural and functional brain networks in Smith-Magenis Syndrome and relat
Dr. Xiaolu STURGEON – Aurora, Colorado
2009-2010: Down syndrome and intellectual disability gene networks
T:
Pr. Alan TARTAKOFF – Cleveland, Ohio. [Profile]
2003-2004: Molecular Therapy for Fragile X syndrome
2001-2002: Molecular Therapy for Fragile X syndrome
Dr. Maria TEJADA-SIMON – Houston, Texas. [Profile]
2009-2010: Therapeutic potential of Rac1 inhibitors in cognitive disorders
2007-2008: Therapeutic potential of Rac inhibitors in cognitive disorders
V:
Dr. Jennifer VANNEST – Cincinnati, Ohio. [Profile]
2006-2007: The Neural Basis of Language in neurodevelopmental disorders
W:
Dr. Edwin J. WEEBER – Tampa, Florida. [Profile], [Website]
2009-2010: Therapeutic interventions for Angelman Syndrome
Ms. Katy WONG – Chicago, Illinois
2007-2008: The Regulation of Receptor Tyrosine Kinase Trafficking by Intersectin
Dr. Katherina WALZ – Miami, Florida. [Profile]
2010-2011: Exploring the reversibility of neuron functional deficiency
Dr. Jianhua WU – Atlanta, Georgia. [Profile]
2008-2009: Effect of ankle weights on overground walking in preadolescents with and without Down syndrome
Y:
Pr. Paul YAROWSKY – Baltimore, Maryland. [Profile]
2003-2004: Proliferation and survival of neural stem cells adult Ts65Dn mice
2001-2002: Manipulation of adult neurogenesis in mice TS65DN, a model of Down Syndrome
Dr. Juan YOUNG – Miami, Florida. [Profile]
2010-2011: Modulation of Rett-like phenotypes in mouse models of Rett syndrome
Dr. Eugene YU – Buffalo, New York. [Profile]
2005-2006: Characterization of new mouse models of Trisomy 21 chromosomes developed by engineering
2007-2008: Effects of human chromosome 21 synthetic regions and Dyrk1 on Trisomy 21-related phenotypes in mice
U.S. Grant Recipients - July 1, 2012 to June 30, 2013
Dr. Emily BROOKES
Elucidating the role of histone demethylase SMCX in intellectual disability unsing human induced pluripotent stem cells
Dr. Aurore CURIE
Study of neuronal networks and cognitive mechanisms involved in X linked intellectual disability
Dr. Kathleen GARDINER
Workshop on Cognition in Down syndrome: molecular, cellular and behavioral features and the promise of therapeutics
U.S. Grant Recipients - July 1, 2011 to June 30, 2012:
Dr. Katheleen GARDINER
Comparative analysis of drug responses in mouse models of Down syndrome
Dr. Kyung-Tai MIN
Investigating the biological pathways shared between Down syndrome and Fragile X syndrome
Pr. Lynn NADEL - Tucson, Arizona
High density EEG biomakers of memory dysfunction in Down syndrome
Mr. Mustafa Nazir OKUR – Chicago, Illinois
Intersectin regulation of EGFR ubiquitylation and degradation
U.S. Grant Recipients - July 1, 2010 to June 30, 2011:
Dr. Sarah ELSEA – Richmond, Virginia
Development and characterization of a neuronal model system for analysis of compounds to modulate RAI1 expression in Smith-Magenis syndrome
Pr. Randall ROPER – Indianapolis, Indiana
Mechanism of craniofacial and appendicular bone development disrupted by trisomy in Down syndrome
Dr. Katherina WALZ – Miami, Florida
Exploring the reversibility of neuron functional deficiency
Dr. Juan YOUNG – Miami, Florida
Modulation of Rett-like phenotypes in mouse models of Rett syndrome
U.S. Grant Recipients - July 1, 2009 to June 30, 2010:
Dr. Gilbert DI PAOLO – New York, New York
Lipid Imbalance and endosomal dysfunction in Down syndrome – A lipidomic approach
Dr Maria TEJADA-SIMON – Houston, Texas
Therapeutic potential of Rac1 inhibitors in cognitive disorders
Dr Xiaolu STURGEON – Aurora, Colorado
Down syndrome and intellectual disability gene networks
Dr. Dana CRAWFORD – Albany, New York
The role and targeting of RCAN1 in Down Syndrome
Dr. Jamie EDGIN – Tucson, Arizona
Aging and Dementia in Down Syndrome: Neuropsychological Profile and Intervention
Ms. Janet L HAUCK. – Ann Arbor, Michigan
Promoting physical activity in young children with Down syndrome
Pr. Jan Peter KRAUS – Aurora, Colorado
Targeting misfolding in homocystinuria
Dr. Edwin J. WEEBER – Tampa, Florida
Therapeutic interventions for Angelman Syndrome
Dr. Katheleen GARDINER – Denver, Colorado
Perturbation of signaling pathways in the Tc1 mouse model of Down Syndrome
U.S. Grant Recipients - July 1, 2008 to June 30, 2009:
Dr. Shannon RINGENBACH – Tempe, Arizona
Examination of intra and interhemispheric processing following different instructiong during long term motor learning in persons with Down syndrome
Dr. Katheleen GARDINER – Denver, Colorado
Stabilizing post translational modification (PTM) in tissue samples
Dr. Sarah ELSEA – Richmond, Virginia
Defining the critical genes for disorders of behavior and developmental delay on chromosomes 2q37.3 and 2q23.1
Dr. Terry ELTON – Colombus, Ohio
Down Syndrome and MicroRNAs
Dr. Sandra RYEOM – Boston, Massachussetts
Down Syndrome: Protection against cancer and the role of the Down syndrome candidate region-1 gene
Dr. Heather LEHMAN – Buffalo, New York
Humoral Immunodeficiency in Pediatric Down Syndrome Patients
Dr. Jianhua WU - Atlanta, Georgia
Effect of ankle weights on overground walking in preadolescents with and without Down syndrome
Dr. John O’BRYAN – Chicago, Illinois
Defining intersectin (ITSN) function in Down Syndrome
Dr. Kenneth MACLEAN – Aurora, Colorado
Novel Pathogenic Mechanisms and Treatment for Cognitive Impairment in CBS Deficient Homocystinuria
U.S. Grant Recipients - July 1, 2007 to June 30, 2008
Dr. H.Graig HELLER – Stanford, California
GABA based pharmacotherapy essays for improving cognition through the consolidation of sleep and wake in Ts65Dn mice
Ms. Katy WONG – Chicago, Illinois
The Regulation of Receptor Tyrosine Kinase Trafficking by Intersectin
Dr. Anita BHATTACHARYYA – Madison, Wisconsin
Generation of human trisomy 21 pluripotent cells
Ms. Ann C.M SMITH. – Bethesda, Maryland
Comparative Behavioral Phenomics: Investigation of structural and functional brain networks in Smith-Magenis Syndrome and relat
Dr. Gene FISCH – New York, New York
Longitudinal studies of children with subtelomeric deletions causing mental handicap
Dr Maria TEJADA-SIMON – Houston, Texas
Therapeutic potential of Rac inhibitors in cognitive disorders
Dr. Eugene YU – Buffalo, New York
Effects of human chromosome 21 synthetic regions and Dyrk1 on Trisomy 21-related phenotypes in mice
U.S. Grant Recipients - July 1, 2006 to June 30, 2007
Dr. Shannon RINGENBACH – Tempe, Arizona
Music and Movement in Persons with Down Syndrome
Dr. Yu-Wen HWANG– Staten Island, New York
Regulation Of The assembly of endocytic complex by Dyrk1A
Dr. Alberto COSTA – Denver, Colorado
Preclinical Development of Targeted Pharmacotherapy at Associated Hypomyelination to Down Syndrome
Dr. Jennifer VANNEST– Cincinnati, Ohio
The Neural Basis of Language in neurodevelopmental disorders
Pr. Jan KRAUS – Aurora, Colorado
CBS: A Key Enzyme Involved in homocysteine metabolism and hydrogen sulfide
Dr. Jean-Bernard MANENT– Storrs, Connecticut
Investigating the reversibility of neuronal migration disorders in animal model year of double cortex syndrome
Dr. Gilbert DI PAOLO– New York, New York
Role of the over-expression of Synj1 in cognitive deficits in mouse models for Trisomy 21
Dr. Sarah ELSEA– Richmond, Virginia
Identification of loci responsible for disorders in mental retardation near the Smith-Magenis syndrome
Dr. Katheleen GARDINER – Denver, Colorado
– Conference on the Biology of genes on chromosome 21: correlation to gene/phenotype in Trisomy 21
– Perturbation of signaling pathways: application to cognitive defects and Trisomy 21
– Data mining for gene-phenotype and drug response correlations in Down syndrome
U.S. Grant Recipients - July 1, 2005 to June 30, 2006:
Dr. Kyung-Tai MIN – Bethesda, Maryland
Using Drosophila to study the etiology of Alzheimer’s disease in Trisomy 21
Dr. David PATTERSON – Denver, Colorado
Mouse models over-expressing or knockout the gene of the reduced folate carrier (RFC): study of the role of RFC in Trisomy 21
Pr. Gene FISCH – New York, New York
Longitudinal studies of subtelomeric deletions cause of mental disability
Dr.Eugene YU – Buffalo, New York
Characterization of Trisomy 21 mouse models developed by chromosome engineering
Dr. Michael MILES – Cincinnati, Ohio
Evaluation of effectiveness of coenzyme Q10 (uniquinone) in children with Trisomy 21
U.S. Grant Recipients - July 1, 2004 to June 30, 2005:
Dr. Katheleen GARDINER – Denver, Colorado
Abnormalities of the protein MAP kinase and calcineurin in models of Trisomy 21 mice
Dr. Zygmunt GALDZICKI – Bethesda, Maryland
Signaling pathways in platelets of patients and mouse models of Trisomy 21
Dr. Dana CRAWFORD – Albany, New York
Involvement of neuronal overexpression of the gene adapt78 (DSCR1) in Trisomy 21
Pr. Jan Peter KRAUS – Aurora, Colorado
Mouse models of deficiency Homocystinuria Cystathionine beta synthase (CBS)
Dr. Katheleen GARDINER – Denver, Colorado
A database of chromosome 21/Trisomy 21
U.S. Grant Recipients - July 1, 2003 to June 30, 2004:
Dr. David PATTERSON – Denver, Colorado
Production and use of transgenic mice CBS to understand the role of this enzyme in Trisomy 21
Pr. Emmanuel MIGNOT – Palo Alto, California
The cycle of sleep in a model of Trisomy 21: metabolic implications
Pr. Alan TARTAKOFF – Cleveland, Ohio
Molecular Therapy Fragile X syndrome
Pr. Paul YAROWSKY – Baltimore, Maryland
Proliferation and survival of neural stem cells adult Ts65Dn mice
Dr. Gilbert DI PAOLO – New Haven, Connecticut
Study of the metabolism of PIP2 in a mouse model of Trisomy 21
Mr. Tyler BEST – Bethesda, Maryland
PIP2 modulation of channel current GIRK in Trisomy 21
Grant Recipients - July 1, 2002 to June 30, 2003:
Pr. Mark SCHAPIRO – Cincinnati, Ohio
Studies of language processing by functional MRI in Trisomy 21
Dr. David PATTERSON – Denver, Colorado
Study of mitochondrial proteins during therapeutic interventions in a mouse model of Trisomy 21
Dr. Katheleen GARDINER – Denver, Colorado
– Expert Meeting on the gene-phenotype correlations in Trisomy 21
– Abnormalities of MAP kinase and calcineurin in mouse models of Trisomy 21
U.S. Grant Recipients - July 1, 2001 to June 30, 2002:
Pr. Paul YAROWSKY – Baltimore, Maryland
Manipulation of adult neurogenesis in mice TS65DN, a model of Down Syndrome
Mr. Zygmunt GALDZICKI – Bethesda, Maryland
The impact of kainate receptor over-expression on brain and spinal cord synaptic plasticity in mouse TS65DN – Animal Model of Down Syndrome
Dr. David PATTERSON – Denver, Colorado
Effect of a diet rich in antioxidants to prevent the loss of cholinergic neurons and cognitive decline in mice
Pr. Alan TARTAKOFF – Cleveland, Ohio
Molecular Therapy for Fragile X syndrome
U.S. Grant Recipients - July 1, 2000 to June 30, 2001:
Dr. Katheleen GARDINER – Denver, Colorado
Candidate genes involved in the phenotype of Trisomy 21: analysis of their expression in cell lines of normal and Trisomy 21 and in murine models
U.S. Grant Recipients - July 1, 1999 to June 30, 2000:
Dr. David PATTERSON – Denver, Colorado
Study of the variation in purine diet and folate on a mouse model of Trisomy 21
U.S. Grant Recipients - July 1, 1998 to June 30, 1999:
Dr. Katheleen GARDINER – Denver, Colorado
Analysis of the expression of known genes and new genes in cell lines trisomic and normal, and animal models
